China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
000999
Rank in Stocks
#2914
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent... China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of medicinal products. Its operations span both the People's Republic of China and international markets, additionally providing various health-related services. The company's extensive product line includes a wide range of over-the-counter (OTC) medications addressing common conditions such as colds, skin issues, gastrointestinal complaints, coughs, and needs in orthopedics and pediatrics. It also provides prescription drugs, with a focus on areas like traditional Chinese medicine, oncology, cardiovascular and cerebrovascular health, digestive system disorders, orthopedics, and pediatrics. Further offerings comprise Chinese medicine injections, specialized formula granules, and anti-infective agents. These products are often marketed under popular brand families, notably 999 family medicine, Sanjiuweitai series, 999 Ganmaoling series, and 999 dermatitis series. Founded in 1999 and headquartered in Shenzhen, PRC, the company initially operated as Sanjiu Pharmaceutical Co., Ltd. before rebranding to its current name in February 2010. It functions as a subsidiary under the umbrella of China Resources (Holdings) Co., Ltd.
Share Price
$3.74
Market Cap
$6.23B
Change (1 day)
-2.11%
Change (1 year)
-8.54%
Country
CN
Trade China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)
Category
Healthcare
P/E ratio for China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)
P/E ratio as of October 2026 TTM: 12.63
According to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 12.63. At the end of 2024 the company had a P/E ratio of 16.86.
P/E ratio history for China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. from 2001 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 12.63 | -8.64% |
| 2025 | 13.82 | -18.06% |
| 2024 | 16.86 | -6.37% |
| 2023 | 18.01 | -4.60% |
| 2022 | 18.88 | 15.77% |
| 2021 | 16.30 | 6.54% |
| 2020 | 15.30 | 3.35% |
| 2019 | 14.81 | -11.72% |
| 2018 | 16.77 | -17.96% |
| 2017 | 20.44 | 0.88% |
| 2016 | 20.27 | -4.96% |
| 2015 | 21.32 | -0.27% |
| 2014 | 21.38 | 35.11% |
| 2013 | 15.83 | 17.39% |
| 2012 | 13.48 | -21.01% |
| 2011 | 17.07 | -27.93% |
| 2010 | 23.68 | 11.06% |
| 2009 | 21.32 | -1.85% |
| 2008 | 21.72 | -55.50% |
| 2007 | 48.82 | 80.27% |
| 2006 | 27.08 | 71.28% |
| 2005 | 15.81 | -693.03% |
| 2004 | -2.67 | -128.97% |
| 2003 | 9.20 | -20.97% |
| 2002 | 11.65 | -26.66% |
| 2001 | 15.88 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 23.30 | 84.53% |
DE
|
|
| 26.92 | 113.19% |
DE
|
|
| 55.58 | 340.17% |
JP
|
|
| 61.13 | 384.17% |
CH
|
|
| 34.87 | 176.20% |
IN
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.